Metastatic Cancer | HPV Vaccines | Melanoma, Cancer Information Highlights, 10/27/2021

National Cancer Institute sent this bulletin at 10/27/2021 10:54 AM EDT
National Cancer Institute

Having trouble viewing this email? View it as a Web page.

Bookmark and Share
Cancer Information Highlights
From the National Cancer Institute
Updating you about cancer causes, prevention, screening, treatment, coping, and more
 
New from NCI
From Scan to Scan: The Challenges of Living with Metastatic Cancer
back of black jacket that says survivor in big letters   New treatments are helping more people with advanced or metastatic cancer live longer. At a recent NCI conference, survivors and researchers came together to discuss how to better address the needs of those living with metastatic cancer.
More Parents Have Concerns about HPV Vaccines
2 pie charts. one shows that in 2015, 13% of parents had concerns about HPV vaccines. the other shows that in 2018, 23% of parents had concerns   Despite more than 15 years of data that show that HPV vaccines are safe and effective, a new study has found that, in recent years, more parents have concerns about the vaccines’ safety. The findings highlight an urgent need to address these concerns with parents.
Pembrolizumab May Help Prevent Early-Stage Melanoma from Returning

Research results show that people who received the immunotherapy pembrolizumab (Keytruda) after surgery to remove certain melanomas were less likely to have cancer come back than those who did not receive treatment after surgery.
The Tech Revolution in Cancer Research and Care
NCA50 logo   A number of advances in technology have led to breakthroughs in how we find, see, understand, and treat cancer. Read about two of these advances: CRISPR and artificial intelligence.
Computer-Based Drug Design: Advancing the Discovery of New Cancer Medicines
FY23 Annual Plan   Computer technology could help researchers find matches between targets in the body that cause cancer and possible drugs. This section of the NCI Annual Plan & Budget Proposal for Fiscal Year 2023 describes how NCI is poised to make the most out of advances in computer technology to help find new drugs to treat and prevent cancer.
Enhertu May Be Preferred Treatment for Some Breast Cancers

A recent clinical trial showed that a targeted therapy called trastuzumab deruxtecan (Enhertu) lengthened the time that people with an aggressive type of breast cancer lived without their cancer getting worse. Learn more about the therapy, which is made up of a monoclonal antibody linked to a chemotherapy drug, and the ongoing study.
PDQ Updates
Oral Cavity and Nasopharyngeal Cancers Screening

We’ve updated our summary on screening for oral cavity and nasopharyngeal cancers with a new title and revisions to all sections.
FDA Approvals
Oral Treatment for Lung Cancer

We’ve added a new drug summary for mobocertinib succinate (Exkivity). The Food and Drug Administration (FDA) recently approved this oral treatment for non-small cell lung cancer with certain EGFR mutations. The drug is used in adults with locally advanced or metastatic cancer.
Pembrolizumab

We've updated our drug summary on pembrolizumab (Keytruda) with a new FDA approval. The drug was recently approved to treat cervical cancer that has not responded to treatment, has returned, or has spread.
 
Also of Interest
Side Effects of Cancer Treatment

Side effects are problems that occur when treatment affects healthy tissues or organs. Learn about the side effects that cancer treatment can cause and ways to manage them.
Contact Us for Help

Information specialists at NCI’s Cancer Information Service (CIS), NCI's contact center, are available to help answer your cancer-related questions in English and Spanish. Reach us by phone, chat, or email.